Literature DB >> 12555216

Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.

Martin H Steinberg1, Ersi Voskaridou, Abdullah Kutlar, Dimitris Loukopoulos, Mabel Koshy, Samir K Ballas, Oswaldo Castro, Franca Barton.   

Abstract

Fetal hemoglobin (HbF) level and the HbF responses to hydroxyurea (HU) vary among patients with sickle cell disease and are, at least in part, genetically regulated. We hypothesized that siblings with sickle cell disease are likely to share the same parental beta-like globin gene clusters with their cis-acting regulatory sequences and therefore, if regulation of this response is linked to the beta-globin gene cluster, might have concordant HbF responses to HU. Accordingly, we studied 26 families (30 sib pairings), 20 with sickle cell anemia (three families had three siblings) and 6 families with HbS-beta-thalassemia (one family had three siblings, and one family consisted of monozygotic twins), to see if siblings with sickle cell disease had discordant or concordant changes in HbF during HU treatment. Intraclass correlation coefficients (r) showed a high, positive correlation between sibs for HbF levels before and during HU treatment and a concordant change in HbF response from baseline to treatment-associated levels. Changes in mean corpuscular volume (MCV) paralleled HbF levels, while the expected correlations between treatment-associated fall in leukocyte count and increase in MCV were also present. Our results provide additional evidence that some elements that regulate HbF expression are linked to the beta-globin gene cluster. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12555216     DOI: 10.1002/ajh.10264

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

Review 1.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 2.  Fetal hemoglobin in sickle cell anemia.

Authors:  Idowu Akinsheye; Abdulrahman Alsultan; Nadia Solovieff; Duyen Ngo; Clinton T Baldwin; Paola Sebastiani; David H K Chui; Martin H Steinberg
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

3.  Hydroxyurea in Sickle Cell Disease: Our Experience in Western India.

Authors:  S V Deshpande; S S Bhatwadekar; Parth Desai; Tarang Bhavsar; Ankit Patel; Amey Koranne; Arpan Mehta; Shweta Khadse
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-16       Impact factor: 0.900

Review 4.  Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.

Authors:  Nancy S Green; Sandra Barral
Journal:  Pediatr Blood Cancer       Date:  2010-09-09       Impact factor: 3.167

5.  Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.

Authors:  Susan E Creary; Chase Beeman; Joseph Stanek; Kathryn King; Patrick T McGann; Sarah H O'Brien; Robert I Liem; Jane Holl; Sherif M Badawy
Journal:  Pediatr Blood Cancer       Date:  2022-04-04       Impact factor: 3.838

6.  Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype.

Authors:  A Driss; K O Asare; J M Hibbert; B E Gee; T V Adamkiewicz; J K Stiles
Journal:  Genomics Insights       Date:  2009-07-30

Review 7.  A comprehensive literature review of haplotyping software and methods for use with unrelated individuals.

Authors:  Rany M Salem; Jennifer Wessel; Nicholas J Schork
Journal:  Hum Genomics       Date:  2005-03       Impact factor: 4.639

Review 8.  Emerging science of hydroxyurea therapy for pediatric sickle cell disease.

Authors:  Nancy S Green; Sandra Barral
Journal:  Pediatr Res       Date:  2013-11-19       Impact factor: 3.756

9.  Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.

Authors:  Vivien A Sheehan; Jacy R Crosby; Aniko Sabo; Nicole A Mortier; Thad A Howard; Donna M Muzny; Shannon Dugan-Perez; Banu Aygun; Kerri A Nottage; Eric Boerwinkle; Richard A Gibbs; Russell E Ware; Jonathan M Flanagan
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

10.  Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.

Authors:  Nancy S Green; Katherine L Ender; Farzana Pashankar; Catherine Driscoll; Patricia J Giardina; Craig A Mullen; Lorraine N Clark; Deepa Manwani; Jennifer Crotty; Sergey Kisselev; Kathleen A Neville; Carolyn Hoppe; Sandra Barral
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.